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Background-—The relationship between light intensity physical activity (PA), which is common in older adults, and cardiovascular
disease (CVD) risk factors is unclear. This study examined associations of accelerometer-measured PA intensity with CVD risk
factors in older women of different race-ethnicities.
Methods and Results-—Cross-sectional analyses were conducted in 4832 women (mean age 78.9 years; 52.5% white, 30.5%
black, 17.1% Hispanic) who were without known CVD and wore triaxial accelerometers a minimum of 4 of 7 days with ≥10 hours/
d awake wear-time. Vector magnitude counts per 15-s epoch were used to define time spent in low light (19–225 counts/15 s),
high light (226–518), and moderate-to-vigorous; ≥519) intensity PA. Fasting CVD biomarkers, resting blood pressure, waist girth,
body mass index, and 10-year predicted CVD risk (Reynolds Risk Score) were measured. After adjusting for age, wear time, race-
ethnicity, and potential confounders, each PA measure was favorably associated with mean high-density lipoprotein, triglyceride,
glucose, C-reactive protein, body mass index, waist girth, and Reynolds Risk Score (P<0.05, all). Associations with mean blood
pressure, insulin, and total and low-density lipoprotein cholesterol were variable. A 30-minute/d increment in PA was associated,
on average, with odds ratios for high predicted CVD risk (Reynolds Risk Score ≥20) of 0.96 (95% confidence interval, 0.92, 1.00),
0.88 (0.83, 0.94), and 0.85 (0.79, 0.91) for low light, high light, and moderate-to-vigorous, respectively, and remained significant
with further mutual control for PA intensity.
Conclusions-—PA measured by accelerometry, including light intensity PA, was associated with lower CVD risk factor levels in
race-ethnically diverse older women. ( J Am Heart Assoc. 2017;6:e007064. DOI: 10.1161/JAHA.117.007064.)
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M ajor modifiable cardiovascular disease (CVD) riskfactors account for a substantial proportion of CVD
incidence,1 and impose greater population burden with
increasing age, particularly in women.2 At age 65, the lifetime
absolute risk of experiencing a primary atherosclerotic CVD
event is 2 to 3 times higher in women with 1 or more major
risk factors when compared with women with optimal risk
factor levels, whereas in men of similar age risk is elevated by
about 1.5-fold.2 Control of modifiable CVD risk factors is the
cornerstone of primary CVD prevention.3 Prominent in
guidelines for improving CVD risk factors are lifestyle
behaviors including regular physical activity.4
Many studies show self-reported physical activity (PA) is
favorably associated with CVD risk factors.5–7 Self-report data
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on PA are prone to measurement error and reporting biases.
Typically, only 10% to 20% of the variance in accelerometer-
measured PA is explained by self-reported activity8; measure-
ment error may be even greater in older adults.9 Associations
between self-reported PA and CVD risk factors, therefore,
could be underestimated. Accelerometer-measured PA is
becoming more cost-efficient for use in large epidemiologic
cohort studies.10 These devices can improve accuracy of
measuring overall PA levels, and importantly could enhance
measurement of habitual light intensity activity, which is a
prominent domain in older adult lives and especially difficult
to assess by questionnaire. It is generally accepted that self-
report and device-based PA assessments are measuring
related, but different aspects of PA (Troiano, 2012).11 This is
not to diminish the potential utility of self-report measures in
certain settings (Pettee, 2012).12 However, to more precisely
determine associations between PA and disease characteris-
tics across the spectrum of PA intensity, accelerometer-based
measures are preferable. Compared with studies using self-
reported PA, fewer studies have been published in which
accelerometer-measured PA has been related to CVD risk
factors in adults.13–25 Previous studies often have included
relatively small sample sizes,16,17,22,24,25 and few have
reported results in older postmenopausal women.17,24 Pub-
lished data pertaining to the relationship between light
intensity PA and CVD risk factors are limited.26 The purpose
of this study was to examine associations between
accelerometer-measured PA and CVD risk factors in a large
cohort of older women of different race-ethnicities, with a
focus on light intensity PA.
Methods
Participants
Women included in the present study were enrolled in the
OPACH (Objective Physical Activity and Cardiovascular
Health) Study, which is a prospective epidemiologic investi-
gation of accelerometer-measured PA levels and incidence of
CVD in women ages 63 to 99 years that is ancillary to the
Women’s Health Initiative (WHI) Program. Details of the
scientific objectives, eligibility, and implementation of the
WHI27 and OPACH10 studies have been published. During
2012 to 2013, 7875 women participated in the WHI Long Life
Study for which examinations were completed in their homes
to collect new data on factors associated with healthy aging
and changing levels of cardiovascular health. Informed
consent was obtained before the home examination, which
included fasting blood draw (serum, EDTA plasma), question-
naires on personal health status and lifestyle habits, mea-
sured height, weight, waist circumference, resting blood
pressure and pulse, and a physical functioning performance
test (Short Physical Performance Battery). A subset of 7048
women in the Long Life Study consented to participate in the
OPACH study and were given an accelerometer, wear
instructions, a sleep log, and an OPACH PA questionnaire.
After the prescribed wear interval, participants mailed the
accelerometer and completed forms back to the WHI
coordinating center. Almost all women (95.3%) returned their
accelerometer, and of these 92.4% (n=6512) had data
available for analysis.
Accelerometer Measure of PA
Participants were asked to wear a triaxial accelerometer
(ActiGraph GT3X+; Pensacola, FL) on their hip placed
anterior to the iliac crest and secured with a belt for 7
consecutive days during waking and sleeping hours except
when bathing or swimming. Acceleration data from the 3
planes were processed with ActiGraph software (ActiLife,
version 6) using 15-s epochs (raw data recorded at 30 Hz)
and the normal filter, and were integrated in a vector
magnitude count by taking the square root of the sum of
squared axes (vertical, anterior–posterior, and medial–lat-
eral). The vector magnitude counts were summarized to
define intensity-specific PA levels that were categorized for
analysis as low light intensity (19–225 counts/15 s), high
light intensity (226–518), moderate-to-vigorous intensity
(MVPA; ≥519), and total PA (≥19 counts/15 s). Low light
corresponds to standing activities with little movement (eg,
wash/dry dishes), high light corresponds to activities such
as slow walking (1.5 mph [0.7 m/s]) on level ground, and
MVPA corresponds to brisk walking (2.0–2.5 mph [0.9–
1.1 m/s]) on level ground. The standard energy expenditure,
Clinical Perspective
What Is New?
• Physical activity (PA) measured by accelerometers is novel
to large epidemiologic studies, and allows for more accurate
classification of overall PA levels as well as lighter intensity
PA that is prevalent in later life and is difficult to quantify by
recall questionnaire.
What Are the Clinical Implications?
• Because several major modifiable cardiovascular disease
risk factors as well as predicted 10-year cardiovascular
disease risk were favorably associated with both light
intensity PA and the guideline-recommended moderate-to-
vigorous PA in women ages 63 to 99 years, clinicians and
public health practitioners should consider the potential
cardiometabolic benefits through promoting light intensity
activities in an aging US population.
• Results suggest that for those older adults interested and
able to do more intensive PA, greater benefits could accrue.
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expressed as metabolic equivalents, corresponding to low
light, high light, and MVPA are 1.6 to 2.2, 2.3 to 2.9, and
≥3.0 metabolic equivalents, when 1 metabolic equivalent is
defined as 3.5 mL O2 uptake/kg body mass/min. The cut
points were derived from a calibration study conducted in
women of similar age and race-ethnicity as the OPACH
cohort,28 which enhances sensitivity of classifying
accelerometer PA levels in this study.
Accelerometer wear was identified using information from
the sleep logs and a computer-based automated algorithm
developed in the OPACH study.29 Nonwear was defined using
a standard protocol.30 To be included in the present analysis,
we required at least 4 of 7 days with ≥10 hours/d of
accelerometer wear. In-bed time was not included in the
present analysis. As the focus of the present study was on
intensity-specific PA levels in relation to CVD risk factors,
sedentary time was not included in this analysis. Controlling
for awake wear-time in our statistical analysis does account,
to an extent, for differences in sedentary time between
participants.
CVD Risk Factor Measures
Fasting blood was obtained by venipuncture at the home visit.
Participants were instructed to fast for 12 hours and refrain
from smoking and vigorous activities before collection. Blood
vials were centrifuged by data collectors within 2 hours of
blood draw, and shipped overnight priority mail to the Fred
Hutchinson Cancer Research Center Specimen Processing
Laboratory. Aliquots were frozen and shipped to the WHI
Biorepository (Fisher Bioservices, Rockville, MD) for long-term
storage at 80°C until analysis. One of the serum aliquots for
each participant was sent from the WHI Biorepository to the
University of Minnesota Fairview ARDL Laboratory for CVD
biomarker testing within 6 to 12 months of the draw date.
Assays were performed using standardized Clinical Laboratory
Improvement Act–approved methods. Coefficients of variation
in replicate quality assurance samples for the CVD risk factors
included in the present study were 2.1% total cholesterol, 3.3%
low-density lipoprotein cholesterol, 2.9% high-density lipopro-
tein cholesterol (HDL), 2.1% triglyceride, 1.8% glucose, 4.9%
insulin, and 2.9% high-sensitivity C-reactive protein (CRP).
Resting blood pressure (BP) was measured (following
5 minutes of sitting quietly) by auscultation using an aneroid
sphygmomanometer and cuff size based on measured arm
circumference. The first and fifth Korotkoff sounds defined
systolic and diastolic BP, respectively, and the average of 2
measures was recorded. Height (cm) and weight (kg) were
measured using a portable scale and stadiometer; body mass
index (BMI; kg/m2) was computed. Waist circumference (cm)
wasmeasured level with the iliac crest using an anthropometric
tape measure. The Reynolds Risk Score (RRS) for 10-year
predicted CVD risk was computed as a summary measure of
cardiovascular risk. The RRS is computed using age, systolic
BP, CRP, total and HDL cholesterol, diabetes mellitus status,
hemoglobin A1c (if diabetic), smoking status, and family history
of premature myocardial infarction, and has been shown to
strongly discriminate actual CVD event risk in the WHI
cohort.31 Hemoglobin A1c is not available in the OAPCH study
and therefore not included in the RRS computation.
Statistical Analysis
Included in the present analysis were 4832 women without
known CVD for whom at least 4 days of ≥10 hours/d of
accelerometer wear and complete CVD risk factor measures
were available. Participant characteristics were described for
the entire cohort, and then compared according to quartiles of
total PA using generalized linear models for continuous
variables and v2 tests for proportions. Linear correlations
between CVD risk factors and PA measures were evaluated
using Spearman correlations controlling for awake accelerom-
eter wear time and age. Mean CVD risk factors were
compared according to quartiles of low light, high light PA,
and MVPA using general linear models first controlling for
accelerometer wear time, age, race-ethnicity, education,
current smoking, alcohol intake, age at menopause, and
Short Physical Performance Battery; additional adjustment for
BMI was performed then. Linear trends were assessed by
assigning the median to PA quartiles entered as an ordinal
term in the model. Multivariable logistic regression analysis
was used to estimate odds ratios and 95% confidence
intervals for clinically relevant levels of CVD risk factors
associated with a 30 minutes/d increment in each PA
measure (separately). Cut points for the CVD measures were
total cholesterol ≥6.2 mmol/L (240 mg/dL), HDL
<1.3 mmol/L (50 mg/dL), triglyceride ≥1.7 mmol/L
(150 mg/dL), systolic BP ≥135 mm Hg, glucose
≥5.4 mmol/L (100 mg/dL), BMI ≥30 kg/m2, CRP >3 mg/L,
and RRS ≥20. The thresholds for HDL, triglyceride, systolic
BP, and glucose correspond to those used to define metabolic
syndrome, and for total cholesterol that which defines a
clinically relevant high level.32 The CRP threshold has
identified those with high risk of atherosclerotic CVD33; and
the RRS threshold has defined women at high risk for a major
CVD event during a 10-year period.31 The RRS has discrim-
inated observed CHD events better than the Framingham
score in the WHI31 and is, therefore, used here. Logistic
regression analyses were completed for the overall cohort and
according to subgroups defined by age (<80, ≥80 years; an
approximate median split) and race-ethnicity (white, black,
Hispanic). Lastly, linear regression was used to examine the
multivariable relationship between PA and RRS, mutually
adjusting for each PA measure in a single model. This provides
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understanding about the relevance of PA intensity with
respect to an association observed with RRS. Analyses were
completed using SAS version 9.4 (SAS Institute, Cary, NC) and
all P values are for 2-sided hypothesis tests at a 0.05.
Results
Characteristics of the overall cohort and according to total PA
levels are shown in Table 1. The mean age among all women
was 78.9 years, 52.5% were white, 79.5% had at least some
college education, 62.9% drank some alcohol, and 2.6% were
current smokers. On average, women had Short Physical
Performance Battery physical functioning scores of 8.3 out of a
possible maximum of 12. About one third of womenwere obese
(BMI ≥30 kg/m2), 33.4% were abdominally obese (waist
>88 cm), and 19.7% and 72.6% had a history of diagnosed or
treated diabetes mellitus and hypertension, respectively.
Compared with women in the lowest quartile of total PA,
those in the highest quartile were younger, less likely to be
white, current smokers, obese or abdominally obese, or have
Table 1. Participant Characteristics for the Overall Cohort and According to Quartiles of Total Physical Activity (N=4832)
Overall Total Physical Activity Quartiles (Min/d) Trend, P Value
<272.0 272.1 to 335.6 335.7 to 401.8 ≥401.9
Age, y 78.96.6 81.86.3 79.86.3 78.26.3 75.76.1 <0.001
63 to 69 469 (9.7) 55 (4.6) 77 (6.4) 116 (9.6) 221 (18.3) <0.001
70 to 79 1879 (38.9) 314 (26.0) 449 (37.2) 513 (42.5) 603 (49.9)
80 to 89 2276 (47.1) 726 (60.1) 629 (52.1) 549 (45.5) 372 (30.8)
≥90 208 (4.3) 113 (9.4) 53 (4.4) 30 (2.5) 12 (1.0)
Race-ethnicity <0.001
White 2535 (52.5) 741 (61.3) 659 (54.6) 605 (50.1) 530 (43.9)
Black 1473 (30.5) 351 (29.1) 382 (31.6) 377 (31.2) 363 (30.1)
Hispanic 824 (17.1) 116 (9.6) 167 (13.8) 226 (18.7) 315 (26.1)
Education 0.16
High school or less 986 (20.5) 250 (20.8) 254 (21.2) 248 (20.6) 234 (19.4)
Some college 1843 (38.4) 479 (39.9) 476 (39.8) 431 (35.9) 457 (37.9)
College graduate 1976 (41.1) 471 (39.3) 467 (39.0) 523 (43.5) 515 (42.7)
Alcohol in past 3 mo <0.001
Nondrinker 1656 (37.1) 472 (43.7) 453 (40.8) 397 (35.0) 334 (29.4)
<1 drink/wk 1501 (33.7) 377 (34.9) 377 (34.0) 379 (33.4) 368 (32.4)
1 to 4 drinks/wk 778 (17.4) 146 (13.5) 159 (14.3) 216 (19.1) 257 (22.6)
≥5 drinks/wk 525 (11.8) 85 (7.9) 121 (10.9) 142 (12.5) 177 (15.6)
Current smoker 114 (2.6) 40 (3.7) 24 (2.2) 28 (2.5) 22 (1.9) 0.05
BMI, kg/m2 28.05.7 29.56.1 28.55.8 27.65.6 26.24.7 <0.001
≥30 (obese) 1445 (30.1) 504 (42.1) 406 (33.8) 320 (26.7) 215 (18.0) <0.001
Waist, cm 89.813.8 94.914.8 91.313.1 88.713.5 84.311.3 <0.001
>88 (abdominal obesity) 1628 (33.4) 587 (48.3) 444 (36.4) 350 (28.7) 247 (20.3) <0.001
SPPB score (range 0–12) 8.32.5 6.92.7 8.12.4 8.72.3 9.32.1 <0.001
Age at menopause, y 48.46.3 48.36.6 48.86.1 48.46.2 48.36.2 0.12
History of diabetes mellitus 953 (19.7) 328 (27.2) 262 (21.7) 211 (17.5) 152 (12.6) <0.001
History of hypertension 3457 (72.6) 987 (83.1) 918 (76.9) 847 (71.2) 705 (59.3) <0.001
Total PA, min/d 339.796.5 220.539.4 304.717.8 367.719.4 465.953.3 <0.001
Low light PA, min/d 189.249.6 136.228.3 177.126.9 203.430.84 240.340.2 <0.001
High light PA, min/d 98.935.5 60.117.8 87.215.1 107.917.8 140.826.5 <0.001
MVPA, min/d 51.534.8 24.315.8 40.321.2 56.326.8 84.937.8 <0.001
Data are meanSD, or N (%). BMI indicates body mass index; PA, physical activity; MVPA, moderate-to-vigorous physical activity; SPPB, short physical performance battery.
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histories of diabetes mellitus or hypertension (P<0.001, all
except smoking, Table 1). Women with higher versus lower
total PA had higher physical functioning scores and alcohol
intake (P<0.001, each). Age at menopause and education
were not associated with total PA levels.
The majority of daily activity time in the overall cohort was
spent in low light intensity PA, the mean of which represented
about 55% of total daily PA time (Table 1). High light intensity
PA and MVPA accounted for the remaining 30% and 15% of
total daily PA time, respectively.
When compared with women included in the present
analysis, those who received but did not return accelerom-
eters (n=569) were slightly older (mean 80.0 years), had
somewhat lower physical function (mean Short Physical
Performance Battery score 7.2), a higher proportion of
racial-ethnic minorities (44.6% white, 42.9% black, and
12.5% Hispanic), were slightly more obese (31.1%), and had
higher proportions of diagnosed diabetes mellitus (23.9%) and
hypertension (75.8%). Women who returned accelerometers
but did not meet the wear criteria for inclusion in the present
analysis (n=363) were similar in the above characteristics as
the women who received but did not return accelerometers,
with the exception of age (mean 78.6 years).
Spearman correlations between CVD risk factors and PA
measures are shown in Table 2. With the exceptions of total
and low-density lipoprotein cholesterol, all CVD measures
were correlated with each PA measure in the expected
direction. Correlations were strongest for age, HDL, BMI and
waist girth and RRS. Age was significantly correlated with
each CVD risk factor except for triglyceride and HDL.
Table 3 presents mean lipids, BP, and RRS in the overall
cohort, as well as adjusted means according to quartiles of
each PA measure. Mean lipids and BP were within clinical
limits, and the mean RRS of 12.7% indicated an intermediate
level of 10-year predicted CVD risk (ie, RRS 10–20%).
Multivariable adjusted mean total and low-density lipoprotein
cholesterol was positively associated with high light and
MVPA (P<0.05, all); further adjustment for BMI eliminated the
associations with high light PA, whereas MVPA remained
statistically significant (P<0.001, each). Mean HDL was
positively associated, and mean triglyceride inversely associ-
ated, with each PA measure when adjusted for all covariables
including BMI (P<0.001, all). Adjusted means for systolic and
diastolic BP were inversely associated with each PA measure
(P<0.05, all); additional adjustment for BMI eliminated
associations for low light and high light PA with systolic BP,
and for high light and MVPA with diastolic BP. Mean RRS was
inversely associated with each PA measure when fully
adjusted for covariables including BMI (P<0.001, all).
Results for measures of insulin-glucose homeostasis, CRP,
and adiposity are shown in Table 4. Mean values for the cohort
tended to be within clinical limits with the exception of CRP
being elevated indicating high CVD risk, and BMI indicating
overweight. Mean glucose was inversely associated with each
PA measure in fully adjusted models (P<0.05, all). Mean insulin
was significantly inversely associated with each PA measure
when adjusted for covariables (P<0.001, each), but was
associated only with MVPA following additional adjustment
for BMI (P<0.001). Each measure of PA was inversely associ-
ated with mean BMI and mean waist (P<0.001, all), and with
mean CRP including when adjusted for BMI (P<0.05, all).
To provide more clinical context to associations with PA
measures, we examined multivariable odds ratios for pres-
ence of clinically relevant levels of CVD measures in relation
to a 30 minute/day increment in PA measures (Table 5).
Among all women, none of the PA measures were associated
with presence of high total cholesterol. Significant inverse
associations were observed for each PA measure with
presence of low HDL and elevated triglyceride. Only MVPA
was associated with lower odds of having elevated systolic
BP. High light and MVPA were inversely associated with
presence of elevated glucose. Each PA measure was signif-
icantly inversely associated with presence of high CRP, and
BMI-defined obesity. High light and MVPA were significantly
inversely associated with high RRS.
We next evaluated these associations in cohort subgroups
defined by age and race-ethnicity (Table 5). The same
Table 2. Age- and Accelerometer Wear-Time Adjusted
Spearman Correlations* Between Physical Activity and
Cardiovascular Health Measures (N=4832)
Cardiovascular
Measure Physical Activity Measure
Total
Low
Light
High
Light MVPA Age
Total cholesterol 0.10 0.04 0.10 0.13 0.06
LDL cholesterol 0.08 0.02 0.07 0.11 0.09
HDL cholesterol 0.23 0.18 0.20 0.16 0.04
Triglyceride 0.18 0.19 0.14 0.09 0.02
Systolic BP 0.09 0.05 0.08 0.08 0.09
Diastolic BP 0.09 0.08 0.07 0.04 0.10
Glucose 0.12 0.07 0.12 0.11 0.01
Insulin 0.21 0.13 0.19 0.14 0.13
C-reactive protein 0.18 0.11 0.20 0.14 0.11
BMI 0.35 0.21 0.38 0.24 0.23
Waist girth 0.37 0.23 0.39 0.28 0.12
RRS 0.23 0.14 0.23 0.21 0.57
Age 0.26 0.12 0.16 0.39 —
Correlations between age and CVD risk factors are unadjusted. BMI, body mass index;
BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MVPA,
moderate-to-vigorous physical activity; RRS, Reynolds Risk Score.
*All correlations are statistically significant (P<0.01) except for LDL with low light
intensity, and age with triglyceride and HDL.
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Table 3. Mean Lipids, Resting Blood Pressure, and Reynolds Risk Score According to Quartiles of Physical Activity (N=4832)
All* Physical Activity Quartile (Min/d) Trend, P Value
1 (Low) 2 3 4 (High)
Total cholesterol (mmol/L) 197.639.6
Low light PA (median) 133.5 171.9 203.1 247.2
Model 1 196.21.2 196.81.1 197.91.1 199.41.2 0.05
Model 2 197.51.2 196.81.1 197.51.1 198.41.2 0.54
High light PA (median) 59.8 85.5 107.9 139.9
Model 1 194.51.2 197.51.1 196.21.1 201.91.2 <0.001
Model 2 196.81.2 197.91.1 195.61.1 199.91.2 0.24
MVPA (median) 15.9 34.7 55.5 92.3
Model 1 193.81.2 194.51.1 199.41.1 202.51.2 <0.001
Model 2 194.61.2 195.31.1 199.31.1 201.11.2 <0.001
LDL-C (mg/dL) 115.534.5
Low light PA
Model 1 115.01.0 114.30.9 115.80.9 116.71.0 0.17
Model 2 115.81.0 114.40.9 115.60.9 116.11.0 0.68
High light PA
Model 1 113.81.0 115.80.9 114.20.9 118.11.0 0.02
Model 2 115.21.1 115.90.9 113.80.9 116.81.1 0.64
MVPA
Model 1 112.51.1 113.10.9 117.10.9 119.11.0 <0.001
Model 2 112.91.1 113.50.9 117.10.9 118.31.1 <0.001
HDL-C (mg/dL) 60.414.5
Low light PA
Model 1 56.50.4 60.80.4 61.40.4 63.20.4 <0.001
Model 2 57.40.4 60.80.4 61.10.4 62.50.4 <0.001
High light PA
Model 1 57.20.4 59.50.4 60.80.4 64.20.4 <0.001
Model 2 58.90.4 59.80.4 60.40.4 62.80.4 <0.001
MVPA
Model 1 58.60.5 59.20.4 60.90.4 63.10.4 <0.001
Model 2 54.20.4 59.70.4 60.80.4 62.00.4 <0.001
Triglyceride (mg/dL) 109.256.9
Low light PA
Model 1 124.71.7 108.91.6 104.71.6 98.41.7 <0.001
Model 2 122.71.7 108.81.6 105.31.6 99.91.7 <0.001
High light PA
Model 1 118.31.7 111.91.6 107.11.6 99.31.8 <0.001
Model 2 114.51.8 111.41.6 108.21.6 102.61.7 <0.001
MVPA
Model 1 115.11.8 112.41.6 107.21.6 102.01.7 <0.001
Model 2 113.71.8 111.11.6 107.31.6 104.61.7 <0.001
Continued
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patterns of associations between each PA measure and
clinically relevant risk factors observed in the overall cohort
were also present in younger and older women, with few
exceptions. Elevated systolic BP was not associated with any
PA measure in either age group, and in younger women,
elevated glucose was not associated with low light or high
light PA and elevated CRP was not associated with low light
PA. Likewise, patterns of association seen in the overall
cohort also tended to be observed for each race-ethnic
subgroup. Statistical significance was more variable across
race-ethnic subgroups because sample sizes were smaller,
especially for Hispanic women in whom estimates were
somewhat less stable. In each race-ethnic subgroup, however,
significant inverse associations for MVPA were present with
presence of low HDL, elevated triglyceride, obesity, elevated
CRP, and high RRS.
Table 3. Continued
All* Physical Activity Quartile (Min/d) Trend, P Value
1 (Low) 2 3 4 (High)
Systolic BP (mm Hg) 125.714.2
Low light PA
Model 1 126.80.4 125.90.4 125.30.4 124.90.4 <0.001
Model 2 126.10.4 125.90.4 125.50.4 125.40.4 0.16
High light PA
Model 1 127.50.4 125.90.4 125.00.4 124.50.4 <0.001
Model 2 126.20.4 125.70.4 125.40.4 125.50.4 0.24
MVPA
Model 1 126.90.4 126.80.4 125.60.4 123.90.4 <0.001
Model 2 126.60.4 125.90.4 125.60.4 124.60.4 0.003
Diastolic BP (mm Hg) 72.48.7
Low light PA
Model 1 73.40.3 72.30.3 72.30.3 71.30.3 <0.001
Model 2 73.10.3 72.30.3 72.40.3 71.60.3 <0.001
High light PA
Model 1 73.20.3 72.60.3 72.30.3 71.40.3 <0.001
Model 2 72.60.3 72.50.3 72.40.2 71.90.3 0.13
MVPA
Model 1 72.70.3 72.60.3 72.40.2 71.80.2 0.02
Model 2 72.50.3 72.40.3 72.40.3 72.20.3 0.45
Reynolds Risk Score 12.711.0
Low light PA
Model 1 14.50.3 12.70.3 12.00.3 11.60.3 <0.001
Model 2 13.90.3 12.60.3 12.20.3 11.90.3 <0.001
High light PA
Model 1 15.50.3 12.90.3 11.70.3 10.60.3 <0.001
Model 2 14.70.3 12.80.3 11.90.3 11.40.3 <0.001
Moderate-vigorous PA
Model 1 14.70.3 13.10.3 11.90.3 10.90.3 <0.001
Model 2 14.40.3 12.80.3 12.00.3 11.50.3 <0.001
Quartile range for PA (min/d): Low light PA: ≤154.0, 154.1 to 186.8, 186.9 to 219.8, ≥219.9. High light PA: ≤74.1, 74.2 to 96.5, 96.6 to 121.2, ≥121.3. Moderate-vigorous PA: ≤25.2, 25.3
to 44.5, 44.6 to 69.8, ≥69.9. Model 1: meanSE adjusted for accelerometer wear-time, age, race-ethnicity, education, smoking (except RRS model), alcohol, age at menopause, and SPPB
score. Model 2: meanSE adjusted for above plus BMI. BMI indicates body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; MVPA, moderate-to-vigorous physical activity; PA, physical activity; SPPB, short physical performance battery.
*Unadjusted meanSD for overall cohort. Reynolds Risk Score, the 10-Yr predicted probability (%) of developing CVD
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Table 4. Mean Glucose, Insulin, CRP, BMI, and Waist Girth According to Quartiles of Physical Activity (N=4832)
All* Physical Activity Quartile (Min/d) Trend, P Value
1 (Low) 2 3 4 (High)
Glucose (mg/dL) 98.327.6
Low light PA
Model 1 100.90.8 98.00.8 98.10.8 95.90.8 <0.001
Model 2 99.70.8 97.90.8 98.50.8 96.80.8 0.03
High light PA
Model 1 102.70.8 98.90.8 96.90.8 94.60.8 <0.001
Model 2 100.60.9 99.50.8 97.60.8 96.40.8 <0.001
MVPA
Model 1 102.20.9 100.10.8 96.70.8 93.90.8 <0.001
Model 2 101.50.9 99.40.8 96.80.8 95.30.8 <0.001
Insulin (pmol/L) 92.1122.3
Low light PA
Model 1 103.23.6 89.53.5 93.43.5 82.33.6 <0.001
Model 2 97.33.6 89.13.5 95.23.5 86.73.6 0.13
High light PA
Model 1 109.33.7 93.33.5 87.63.5 78.23.6 <0.001
Model 2 98.53.8 91.73.5 90.63.5 87.53.7 0.06
MVPA
Model 1 103.73.8 98.53.5 93.13.5 73.03.7 <0.001
Model 2 100.23.8 95.03.5 93.53.5 79.63.7 <0.001
CRP (mg/L) 3.68.2
Low light PA
Model 1 4.10.2 3.90.2 3.50.2 3.00.2 <0.001
Model 2 3.90.2 3.90.2 3.60.2 3.20.2 0.03
High light PA
Model 1 4.90.3 3.40.2 3.50.2 2.70.2 <0.001
Model 2 4.50.3 3.30.2 3.60.2 3.00.2 0.001
MVPA
Model 1 4.20.3 3.80.2 3.80.2 2.70.3 <0.001
Model 2 4.00.3 3.70.2 3.90.2 3.00.2 0.02
BMI (kg/m2) 27.95.7
Low light PA
Model 1 29.50.2 28.00.2 27.40.2 26.80.2 <0.001
High light PA
Model 1 30.90.2 28.40.2 27.10.2 25.40.2 <0.001
MVPA
Model 1 28.90.2 28.90.2 27.80.2 26.10.2 <0.001
Waist, cm 77.911.9
Low light PA
Model 1 81.50.3 78.20.3 77.10.3 75.00.3 <0.001
Continued
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To evaluate the robustness of findings for analyses
conducted on each intensity-specific PA measure separately,
we further evaluated their relationships with RRS, used as a
summarymeasure of CVD risk. The figure shows scatterplots of
the inverse age and accelerometer wear time–adjusted rela-
tionships between each PA measure and RRS. We next used
multivariable linear regression to evaluate the relationships
between RRS and each intensity-specific PA measure control-
ling for confounders, with and without mutual adjustment for
each PA measure in a single model. Results are presented in
Table 6 and show significant inverse relationships between
RRS and each PA measure (P<0.001, each) with the strongest
relationship seen for high light PA. Associations were attenu-
ated but generally remained significant (P<0.01) following
further mutual adjustment for each PA intensity.
It is possible that medication use could have influenced
some of the associations observed in this study; however,
information was not available on use of specific medications
that could be relevant. We therefore conducted a sensitivity
analysis excluding women reporting a history of diagnosed
treated diabetes mellitus (n=954) and hypertension (n=3475).
Results were consistent with the primary findings. Age- and
accelerometer wear time–adjusted Spearman correlations for
total PA and fasting glucose and Homeostatic Model Assess-
ment-Insulin Resistance were 0.12 and 0.22 for the overall
cohort, and were0.08 and0.21 after exclusion on diabetes
mellitus. Correlations for total PA with resting systolic BP were
0.08 and 0.03 before and after excluding on hypertension;
and with RRS were 0.23 and 0.14 before and after
excluding on both diabetes mellitus and hypertension. Trends
in means for these risk factors across intensity-specific PA
quartiles, and associations between a 30-minutes/d increment
in PA and clinical levels of these risk factors also were
consistent with the primary results (data not shown).
Discussion
The main findings of this large cross-sectional study in race-
ethnically diverse older postmenopausal women are that
greater amounts of accelerometer-measured total, light, and
MVPA were associated with better levels of a number of
modifiable major CVD risk factors; with lower odds of having
prevalent clinically relevant risk factor levels; and with lower
predicted 10-year CVD risk. The associations were observed
after adjustments for several relevant confounding factors
including objectively measured physical functioning and BMI,
and generally were consistent when stratified across age
and race-ethnic subgroups. A major novel finding of the
present study is the beneficial associations of PA at
intensities below MVPA, which typically is recommended
for health benefits including control of CVD risk factors.
Indeed, the majority of the cardiometabolic factors evaluated
among these older women showed favorable associations
with low- and high light intensity PA that were statistically
significant when adjusted for a range of confounding
influences. These results add important information to the
sparse but growing evidence regarding the health benefits of
light intensity PA.26 Furthermore, to our knowledge, this is
one of the first large epidemiologic studies to relate
accelerometer measures of intensity-specific PA with pre-
dicted CVD risk (RRS) and cardiometabolic risk factors in a
defined cohort of older postmenopausal women. Because
the population burden of CVD will grow in parallel with the
growth of the 65 and older age group in coming decades,
the present results have relevance to both public health and
healthy aging.
Few published studies have reported on relationships
between accelerometer-measured PA and CVD risk factors
specifically in older women. Gando et al17 observed a
significant inverse relationship between HOMA insulin resis-
tance scores and incremental quartiles of light intensity PA
measured using a triaxial accelerometer, after adjusting for
age, waist circumference, cardiorespiratory fitness, and
accelerometer-measured MVPA in 198 women who were, on
average, 59 years of age and had low fitness levels.
Accelerometer cut points used to define light PA were not
reported, which limits precise comparison to our results.
However, the inverse relationship with light PA and insulin–
Table 4. Continued
All* Physical Activity Quartile (Min/d) Trend, P Value
1 (Low) 2 3 4 (High)
High light PA
Model 1 84.10.3 78.70.3 76.50.3 72.50.3 <0.001
MVPA
Model 1 80.90.3 79.90.3 77.60.3 73.30.3 <0.001
Quartile range (footnoted) and medians for PA min/d same as in Table 2. Model 1: meanSE adjusted for accelerometer wear-time, age, race-ethnicity, education, smoking, alcohol, age at
menopause, and SPPB score. Model 2: meanSE adjusted for above plus BMI (except for BMI and waist models). BMI indicates body mass index; CRP, C-reactive protein; MVPA, moderate-
to-vigorous physical activity; PA, physical activity; SPPB, short physical performance battery.
*Unadjusted meanSD for overall cohort.
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Table 5. Odds Ratios and 95% Confidence Intervals for Clinically Relevant Values of Cardiovascular Health Measures Associated
With a 30-Min/d Increment in Physical Activity, Among All Women and Cohort Subgroups (N=4832)
All <80 years ≥80 years White Black Hispanic
N 4832 2348 2484 2535 1473 824
Chol ≥240
Cases, N (%) 677 (14.0) 376 (16.0) 301 (12.1) 350 (13.8) 201 (13.6) 126 (15.3)
Low light PA 0.99 (0.94, 1.05) 0.93 (0.86, 1.01) 1.06 (0.98, 1.14) 0.98 (0.91, 1.06) 1.02 (0.92, 1.13) 0.97 (0.85, 1.11)
High light PA 0.96 (0.89, 1.05) 0.99 (0.88, 1.11) 0.95 (0.84, 1.07) 0.92 (0.82, 1.03) 1.05 (0.90, 1.23) 0.96 (0.79, 1.17)
MVPA 1.03 (0.96, 1.12) 1.06 (0.96, 1.16) 0.98 (0.86, 1.13) 1.04 (0.94, 1.17) 0.95 (0.81, 1.12) 1.08 (0.91, 1.27)
HDL-C <50
Cases, N (%) 1161 (24.0) 581 (24.7) 580 (23.3) 625 (24.7) 309 (20.9) 227 (27.6)
Low light PA 0.87 (0.82, 0.91) 0.89 (0.85, 0.95) 0.86 (0.80, 0.92) 0.86 (0.80, 0.92) 0.93 (0.85, 1.01) 0.91 (0.81, 1.02)
High light PA 0.83 (0.78, 0.89) 0.84 (0.76, 0.93) 0.83 (0.75, 0.92) 0.79 (0.72, 0.88) 0.85 (0.74, 0.98) 0.88 (0.75, 1.03)
MVPA 0.81 (0.75, 0.88) 0.79 (0.92, 0.87) 0.89 (0.74, 0.95) 0.78 (0.69, 0.87) 0.80 (0.69, 0.93) 0.82 (0.70, 0.95)
Trig ≥150
Cases, N (%) 838 (17.3) 389 (16.6) 449 (18.1) 507 (20.0) 122 (8.3) 209 (25.4)
Low light PA 0.79 (0.75, 0.84) 0.83 (0.77, 0.89) 0.78 (0.73, 0.84) 0.80 (0.75, 0.86) 0.89 (0.79, 1.02) 0.87 (0.78, 0.98)
High light PA 0.85 (0.77, 0.90) 0.90 (0.80, 1.01) 0.78 (0.69, 0.87) 0.78 (0.69, 0.87) 0.78 (0.64, 0.97) 0.90 (0.77, 1.05)
MVPA 0.89 (0.83, 0.97) 0.92 (0.83, 1.02) 0.85 (0.75, 0.97) 0.89 (0.79, 1.00) 0.78 (0.62, 0.98) 0.82 (0.71, 0.96)
SBP ≥135
Cases 1160 (24.1) 489 (20.5) 671 (27.0) 635 (25.1) 361 (24.5) 164 (19.9)
Low light PA 0.99 (0.94, 1.03) 0.99 (0.93, 1.06) 0.97 (0.92, 1.04) 0.98 (0.92, 1.04) 0.95 (0.88, 1.03) 1.06 (0.94, 1.19)
High light PA 0.99 (0.93, 1.06) 0.95 (0.86, 1.05) 1.02 (0.94, 1.12) 0.99 (0.91, 1.09) 0.91 (0.80, 1.04) 1.15 (0.97, 1.36)
MVPA 0.93 (0.96, 0.99) 0.93 (0.84, 1.02) 0.93 (0.83, 1.03) 0.89 (0.80, 0.98) 1.02 (0.89, 1.16) 0.91 (0.97, 1.08)
Gluc ≥100
Cases 1514 (31.3) 757 (31.8) 757 (30.5) 769 (30.3) 478 (32.5) 267 (32.4)
Low light PA 0.96 (0.92, 1.00) 0.99 (0.94, 1.06) 0.93 (0.87, 0.98) 0.94 (0.88, 0.99) 1.01 (0.93, 1.08) 0.96 (0.87, 1.07)
High light PA 0.88 (0.83, 0.94) 0.95 (0.87, 1.04) 0.82 (0.75, 0.89) 0.85 (0.78, 0.93) 0.88 (0.79, 0.99) 0.96 (0.82, 1.11)
MVPA 0.85 (0.79, 0.91) 0.83 (0.77, 0.91) 0.88 (0.79, 0.98) 0.87 (0.79, 0.96) 0.84 (0.74, 0.96) 0.81 (0.70, 0.94)
CRP ≥3
Cases 1504 (31.3) 832 (34.9) 672 (27.1) 674 (26.6) 584 (39.7) 246 (29.9)
Low light PA 0.95 (0.91, 0.99) 0.98 (0.92, 1.04) 0.92 (0.86, 0.98) 0.91 (0.86, 0.97) 0.98 (0.91, 1.06) 0.93 (0.83, 1.04)
High light PA 0.85 (0.79, 0.90) 0.89 (0.81, 0.98) 0.79 (0.72, 0.88) 0.85 (0.78, 0.94) 0.84 (0.74, 0.94) 0.83 (0.71, 0.97)
MVPA 0.86 (0.80, 0.92) 0.87 (0.79, 0.95) 0.85 (0.76, 0.95) 0.87, 0.78, 0.96) 0.86 (0.76, 0.97) 0.88 (0.76, 1.02)
BMI ≥30
Cases 1445 (29.9) 867 (36.9) 578 (23.3) 638 (25.2) 579 (39.3) 228 (27.7)
Low light PA 0.78 (0.75, 0.82) 0.81 (0.76, 0.86) 0.74 (0.69, 0.79) 0.72 (0.67, 0.77) 0.83 (0.77, 0.89) 0.77 (0.69, 0.87)
High light PA 0.48 (0.45, 0.52) 0.48 (0.43, 0.53) 0.47 (0.42, 0.53) 0.44 (0.39, 0.49) 0.52 (0.46, 0.58) 0.52 (0.43, 0.61)
MVPA 0.66 (0.62, 0.72) 0.66 (0.60, 0.72) 0.69 (0.61, 0.78) 0.62 (0.55, 0.69) 0.74 (0.66, 0.84) 0.67 (0.57, 0.79)
RRS ≥20
Cases 823 (17.0) 152 (6.5) 671 (27.0) 531 (20.9) 208 (14.1) 84 (10.2)
Low light PA 0.96 (0.92, 1.00) 0.86 (0.76, 0.96) 0.89 (0.83, 0.95) 0.91 (0.85, 0.98) 0.80 (0.72, 0.89) 0.79 (0.66, 0.94)
High light PA 0.88 (0.83, 0.94) 0.69 (0.57, 0.84) 0.76 (0.69, 0.84) 0.83 (0.74, 0.93) 0.61 (0.50, 0.73) 0.68 (0.54, 0.89)
MVPA 0.85 (0.79, 0.91) 0.56 (0.45, 0.71) 0.73 (0.65, 0.83) 0.73 (0.64, 0.84) 0.62 (0.49, 0.79) 0.65 (0.49, 0.87)
OR and 95% CI adjusted for accelerometer wear time, age, race-ethnicity (except race-ethnicity strata), education, smoking (except RRS model), alcohol, age at menopause, SPPB score,
and BMI (except BMI model). Clinically relevant values for cardiovascular health measures: Chol, Total cholesterol ≥240 mg/dL; HDL-C <50 mg/dL; Trig, Triglyceride ≥150 mg/dL; SBP,
Systolic BP ≥135 mm Hg; Gluc, Glucose ≥100 mg/dL; CRP, C-reactive protein ≥3 mg/L; BMI ≥30 kg/m2; RRS, Reynolds Risk Score ≥20%. BMI indicates body mass index; Chol, total
cholesterol; CI, confidence interval; CRP, C-reactive protein; Gluc, glucose; HDL-C, high-density lipoprotein cholesterol; MVPA, moderate-to-vigorous physical activity; OR, odds ratio; RRS,
Reynolds Risk Score predicted 10-y CVD risk; PA, physical activity; SBP, systolic blood pressure; SPPB, short physical performance battery; Trig, triglyceride.
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glucose homeostasis is consistent with our observations for
both fasting insulin and glucose. Buman et al34 reported a
significant inverse relationship between BMI and both low-
and high light PA measured using a uniaxial accelerometer in
482 women aged >65 years. Again, a direct contrast of these
findings with ours requires caution, given differences in the
type of accelerometer; however, we also observed consistent
inverse associations for both BMI and waist circumference
with low- and high light PA. In our study, mean RRS scores
and multivariable odds of clinically relevant RRS (≥20%) were
significantly and inversely related with low- and high light PA,
an impressive result given that the women studied here had,
on average, a relatively low RRS (mean, 12.7%). The finding of
a relationship between accelerometer-measured PA and
predicted CVD risk aligns with a recent report from the LIFE
Trial in which triaxial accelerometer vector magnitude counts
(100–499 counts/min), marginally above threshold defining
sedentary (<100), were associated with lower predicted CVD
risk based on the Framingham score in ambulatory frail adults
ages 70 to 89 who were without known CVD.16 Even after
mutual adjustment for PA intensity, both low- and high light
PA were significantly and inversely associated with RRS in the
OPACH women, which suggests that PA of sufficient volume
likely contributes to CVD risk factors independent of PA
intensity. This important issue requires further clarification.
The cardiometabolic benefit of lighter intensity PA among
older women seen in our study and others is consistent with
cross-sectional findings reported in US adults 20 years and
older who participated in the 2003 to 2006 National Health
and Nutrition Examination Survey.18,35 Favorable age- and
sex-adjusted associations were observed for uniaxial
accelerometer-measured light intensity PA with BMI, waist,
systolic blood pressure, triglyceride, HDL, CRP, and insulin,
and generally were consistent for both low- and high light PA,
defined by splitting at the midpoint the range of accelerom-
eter counts for overall light PA.18 It is possible that these
relationships with light intensity PA are, in part, why lower
mortality risk was observed in relation to light PA in the
National Health and Nutrition Examination Survey, interest-
ingly with a greater benefit among women.36 Unlike in the
OPACH study that is based on age-relevant calibrated
accelerometer intensity cut points, it is unclear the extent
to which the approach to defining low- and high light PA in the
National Health and Nutrition Examination Survey study
accurately reflects the phenotype across the wide age
distribution of women and men studied. Notwithstanding,
there is growing evidence that supports cardiometabolic and
other health benefits in women and older adults at PA levels
of lower intensity than currently recommended for public
health.26 Given the relatively high proportion of daily PA time
spent in lower-intensity activities among women and older
adults,16,36,37 if confirmed, these findings have important
implications for expanding public health recommendations on
PA in an aging society.
The intriguing observations pertaining to light intensity PA
and cardiometabolic risk factors among older women studied
herein should not overshadow the other important result of
Figure. Age- and accelerometer wear-time adjusted Spearman
correlations between Reynolds Risk Score and PA measures.
MVPA indicates moderate-to-vigorous physical activity; PA,
physical activity.
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this study reinforcing recommendations that higher MVPA is
associated with better CVD risk factors and predicted short-
term CVD risk. In most instances, the strongest relationship
among PA variables with CVD risk factors was with MVPA,
which was statistically significant (few exceptions) even with
adjustment for measured physical functioning. Each 30-
minute/d increment in MVPA was, for example, associated
with 34%, 14%, and 15% lower multivariable odds of clinically
relevant levels of BMI, CRP, and RRS predicted CVD risk,
respectively. These results should be interpreted with the
caveat that the relatively older OPACH cohort had, on
average, low CVD risk factors (except CRP, mean 3.6 mg/L)
and lower 10-year predicted risk than what might be expected
in a broader population of women similar in age and race-
ethnic distribution. Associations could be even stronger in
older adults with more adverse CVD risk factors.
Numerous mechanisms support the plausibility of these
cross-sectional results. Laboratory and clinical studies using
animal and human models have documented a variety of
acute and longer-term structural and functional responses to
regular PA that improve both physical performance and
chronic disease risk factors.38 The influence of even small
amounts of low intensity PA on skeletal muscle fiber
distribution and its metabolic attributes39,40 as well as on
endothelial cell function41,42 seems particularly relevant at
advanced ages and is responsive to lighter intensity PA.40,41
This may be an important context in which to consider the
strong findings supporting cardiometabolic benefit associated
Table 6. Multivariable Linear Regression of Reynolds Risk Score on Physical Activity With and Without Mutual Adjustment for
Physical Activity Intensity (N=4832)
Without Mutual PA Adjustment With Mutual PA Adjustment
Physical Activity b 95% CI P Value b 95% CI P Value
All (N=4832)
Low light 0.624 0.800, 0.447 <0.001 0.339 0.574, 0.104 0.002
High light 1.218 1.512, 0.924 <0.001 0.726 1.079, 0.373 <0.001
Moderate-vigorous 0.858 1.155, 0.564 <0.001 0.459 0.753, 0.165 0.004
Age <80 y (N=2348)
Low light 0.351 0.527, 0.175 <0.001 0.210 0.436, 0.015 0.067
High light 0.738 1.032, 0.444 <0.001 0.288 0.669, 0.096 0.142
Moderate-vigorous 0.667 0.901, 0.431 <0.001 0.522 0.237, 0.807 <0.001
Age ≥80 y (N=2484)
Low light 0.798 1.092, 0.504 <0.001 0.504 0.153, 0.858 0.005
High light 1.473 1.885, 1.061 <0.001 0.753 0.135, 1.368 0.02
Moderate-vigorous 1.281 0.059, 0.026 <0.001 0.741 0.123, 1.362 0.02
White (N=2535)
Low light 0.675 0.969, 0.381 <0.001 0.426 0.072, 0.132 0.009
High light 1.227 1.639, 0.815 <0.001 0.663 1.192, 0.134 0.02
Moderate-vigorous 0.873 1.285, 0.461 <0.001 0.537 0.949, 0.125 0.03
Black (N=1473)
Low light 0.684 0.978, 0.390 <0.001 0.240 0.534, 0.054 0.27
High light 1.455 1.925, 0.985 <0.001 1.101 1.807, 0.395 0.002
Moderate-vigorous 0.978 1.507, 0.449 <0.001 0.300 0.888, 0.288 0.35
Hispanic (N=824)
Low light 0.411 0.764, 0.058 0.017 0.315 0.668, 0.038 0.15
High light 0.615 1.085, 0.145 0.011 0.180 0.827, 0.467 0.63
Moderate-vigorous 0.495 0.965, 0.025 0.028 0.381 0.851, 0.089 0.15
Regression coefficient (b) is the mean difference in RRS for, on average, a 30-min/d greater time spent in physical activity. All models are adjusted for accelerometer awake wear time,
age, race-ethnicity (except race-ethnic strata), education, alcohol, age at menopause, SPPB score, and BMI. Mutual adjustment refers to a model that simultaneously includes all 3 PA
intensity variables. b indicates linear regression coefficient; BMI, body mass index; CI, confidence interval; PA, physical activity; RRS, Reynolds Risk Score; SPPB, short physical
performance battery.
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with low- and high light PA observed in the OPACH study.
Recent evidence also points to a role for PA to stimulate
microRNA responses that, in turn, may have cardiometabolic
benefit with aging.43 Resistance exercise activities likely
provide important skeletal muscle stimulus that improves
functional and metabolic parameters in aging, independent of
ambulatory aerobic activity.44,45 However, such activity would
not be measured well using hip-worn accelerometers; thus, its
influence in the present study is unclear. A growing body of
evidence indicates that the human response to both acute
and chronic PA exposures is governed to some extent by the
human genome,46 and there could be age-related genotypic
variation in PA effects on cardiometabolic risk.47
A major strength of this investigation is use of a triaxial
accelerometer to improve measurement sensitivity to activity
patterns of lower intensity that are typical among older
women.10,28 Additionally, the use of accelerometer count
thresholds to define PA intensity levels determined in a
laboratory calibration among women of similar age as those
studied here28 is a major advance in large epidemiologic
studies on PA and cardiometabolic risk. The vast majority of
published accelerometer studies have utilized count cut
points derived from the literature, often from studies that
are not sex- or age specific to the target population.48 Use of
calibrated intensity cut points should reduce the amount of
misclassification on intensity-specific PA levels (especially
reducing underestimation of MVPA) and, thus, improve the
accuracy and precision of estimated associations with CVD
measures. Standardized blood collection, processing, storage,
and bioassays enhance confidence in the CVD biomarker
measurements and lower concern about misclassification
when categorized into clinically relevant levels. The large
samples size and availability of information on a variety of
relevant covariables allowed for use of statistical procedures
to control for potential confounding and stratification to
understand whether primary study results applied within
cohort subgroups defined by age and race-ethnicity.
Limitations include the cross-sectional study design, which
precludes interpretation of results in a cause-related context.
PA intensity, as examined herein, was defined on an absolute
scale. However, because of the age-related decline in aerobic
capacity,49 even lighter intensity activity defined on an
absolute scale may, in fact, reflect a higher relative intensity
for an older as compared with a younger adult. We were
unable to evaluate relative PA intensity in OPACH, and its
influence on CVD risk factors in older adults requires
clarification. We only had available a single accelerometer
measurement to define the PA exposure variables, though a
recent study in older women suggests this probably reflects
reasonably well PA habits over a 1- to 3-year period.50
Cumulative PA exposure determined by repeated accelerom-
eter assessments, if a better representation of usual PA
patterns, could potentially enhance associations with CVD
measures. Self-selection into the study group who returned
accelerometers and who met minimum wear adherence for
inclusion in the present analysis could be a concern. The
proportion of returned accelerometers was remarkably high
(95.3%) in as large a base cohort studied here. Compliance
with accelerometer wear instructions was not perfect, though
it too was exceptionally high (93% meeting definition of
sufficient wear days) given the age group studied. Indeed,
returned devices by mail and compliance with wear instruc-
tions have been lower in other studies on accelerometer-
measured PA in multiethnic older US adults.51 OPACH women
who did not return accelerometers or who did not meet
minimum wear criteria tended to be slightly older, more
racially-ethnically diverse, and had less favorable health
characteristics than did those included in the present study.
Because the number of women who did not return devices or
who did not meet wear criteria was so small relative to the
large study group herein, it is unlikely that the small
differences in characteristics between women included and
not included meaningfully influenced the results of the
present analysis. Controlling for accelerometer wear time
and limiting the present study to only women with at least 4
out of 7 days with 10 or more hours/d of wear reduces the
extent to which results are influenced by variation in
accelerometer wear among studied women, and are recom-
mended procedures for studies on older adults.52 We were
not able to control for use of specific medications that could
be relevant to this analysis, such as antihypertensives, insulin
sensitizers, or lipid-lowering agents. However, sensitivity
analyses in which we excluded women who reported a history
of diagnosed treated diabetes mellitus or hypertension
produced results similar to our primary analysis, although
residual confounding by medication use could still have been
present. Subgroup analyses, particularly in Hispanic women,
may have had limited statistical power, so this should be
considered when interpreting those results. The strength of
associations observed in the women studied here is likely
constrained by their relatively low CVD risk factor levels and
low RRS predicted 10-year CVD risk. Given the older ages of
the women studied in OAPCH, the present findings could have
been influenced to an extent by survivorship effect and thus
likely do not extend to younger ages. Results from additional
accelerometer studies in cohorts with a broader range of adult
ages and more severe risk factor profiles would provide
helpful context and clarification to the present findings.
In conclusion, in a large cohort of ambulatory community-
dwelling older postmenopausal women enrolled in the OPACH
study, accelerometer-measured light intensity PA as well as
MVPA were associated with better CVD risk factor levels, with
lower prevalence of clinically relevant risk factors, and with
lower predicted 10-year CVD risk. Findings from our mutually
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PA adjusted analysis suggest that light PA contributes to
better CVD risk factor levels in addition to, and independent
of, MVPA. This important finding, with substantial public
health relevance, needs to be confirmed by other investiga-
tors in longitudinal study designs. Notwithstanding, our
results not only support current PA recommendations that
encourage MVPA for control of modifiable CVD risk factors,
but also suggest that in older adults even lighter intensity PA
may confer meaningful risk factor benefit. The extent that
these observations extend to associations between
accelerometer-measured PA and CVD incidence needs to be
determined and is a forthcoming investigation in the OPACH
study.
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